** Shares of drug developer Pliant Therapeutics PLRX.O fall 65.5% to $2.72 in extended trading
** Company says a mid-stage trial testing experimental drug bexotegrast in patients with idiopathic pulmonary fibrosis has been paused
** Says enrollment and dosing has been paused while a Data Safety Monitoring Board (DSMB) reviews its trial data
** A DSMB refers to an independent group of experts that reviews clinical trial data to ensure the safety of participants and the validity of the trial
** Idiopathic pulmonary fibrosis is a chronic lung disease that causes scarring and stiffening of the lung tissue
** Up to last close, stock down 40.9% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.